| pubmed-article:18637032 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18637032 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:18637032 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:18637032 | lifeskim:mentions | umls-concept:C1122962 | lld:lifeskim |
| pubmed-article:18637032 | lifeskim:mentions | umls-concept:C1443775 | lld:lifeskim |
| pubmed-article:18637032 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
| pubmed-article:18637032 | lifeskim:mentions | umls-concept:C1511636 | lld:lifeskim |
| pubmed-article:18637032 | lifeskim:mentions | umls-concept:C0750502 | lld:lifeskim |
| pubmed-article:18637032 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:18637032 | pubmed:dateCreated | 2008-11-3 | lld:pubmed |
| pubmed-article:18637032 | pubmed:abstractText | Gefitinib inhibits epidermal growth factor receptor (EGFR) signalling, but may also act by non-EGFR dependent mechanisms. We have investigated the activity of gefitinib in haematological tumour cells, in particular acute myeloblastic leukaemia (AML). | lld:pubmed |
| pubmed-article:18637032 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18637032 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18637032 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18637032 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18637032 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18637032 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18637032 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18637032 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18637032 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18637032 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18637032 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18637032 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:18637032 | pubmed:issn | 1600-0609 | lld:pubmed |
| pubmed-article:18637032 | pubmed:author | pubmed-author:HenrikssonRog... | lld:pubmed |
| pubmed-article:18637032 | pubmed:author | pubmed-author:ErikssonAnnaA | lld:pubmed |
| pubmed-article:18637032 | pubmed:author | pubmed-author:LarssonRolfR | lld:pubmed |
| pubmed-article:18637032 | pubmed:author | pubmed-author:NygrenPeterP | lld:pubmed |
| pubmed-article:18637032 | pubmed:author | pubmed-author:AleskogAnnaA | lld:pubmed |
| pubmed-article:18637032 | pubmed:author | pubmed-author:HöglundMartin... | lld:pubmed |
| pubmed-article:18637032 | pubmed:author | pubmed-author:GrundmarkBirg... | lld:pubmed |
| pubmed-article:18637032 | pubmed:author | pubmed-author:LindhagenElin... | lld:pubmed |
| pubmed-article:18637032 | pubmed:author | pubmed-author:WickströmMali... | lld:pubmed |
| pubmed-article:18637032 | pubmed:author | pubmed-author:DanielssonKat... | lld:pubmed |
| pubmed-article:18637032 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18637032 | pubmed:volume | 81 | lld:pubmed |
| pubmed-article:18637032 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18637032 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18637032 | pubmed:pagination | 344-53 | lld:pubmed |
| pubmed-article:18637032 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:18637032 | pubmed:meshHeading | pubmed-meshheading:18637032... | lld:pubmed |
| pubmed-article:18637032 | pubmed:meshHeading | pubmed-meshheading:18637032... | lld:pubmed |
| pubmed-article:18637032 | pubmed:meshHeading | pubmed-meshheading:18637032... | lld:pubmed |
| pubmed-article:18637032 | pubmed:meshHeading | pubmed-meshheading:18637032... | lld:pubmed |
| pubmed-article:18637032 | pubmed:meshHeading | pubmed-meshheading:18637032... | lld:pubmed |
| pubmed-article:18637032 | pubmed:meshHeading | pubmed-meshheading:18637032... | lld:pubmed |
| pubmed-article:18637032 | pubmed:meshHeading | pubmed-meshheading:18637032... | lld:pubmed |
| pubmed-article:18637032 | pubmed:meshHeading | pubmed-meshheading:18637032... | lld:pubmed |
| pubmed-article:18637032 | pubmed:meshHeading | pubmed-meshheading:18637032... | lld:pubmed |
| pubmed-article:18637032 | pubmed:meshHeading | pubmed-meshheading:18637032... | lld:pubmed |
| pubmed-article:18637032 | pubmed:meshHeading | pubmed-meshheading:18637032... | lld:pubmed |
| pubmed-article:18637032 | pubmed:meshHeading | pubmed-meshheading:18637032... | lld:pubmed |
| pubmed-article:18637032 | pubmed:meshHeading | pubmed-meshheading:18637032... | lld:pubmed |
| pubmed-article:18637032 | pubmed:meshHeading | pubmed-meshheading:18637032... | lld:pubmed |
| pubmed-article:18637032 | pubmed:meshHeading | pubmed-meshheading:18637032... | lld:pubmed |
| pubmed-article:18637032 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18637032 | pubmed:articleTitle | Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia. | lld:pubmed |
| pubmed-article:18637032 | pubmed:affiliation | Division of Clinical Pharmacology, Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden. | lld:pubmed |
| pubmed-article:18637032 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18637032 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:1956 | entrezgene:pubmed | pubmed-article:18637032 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:18637032 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18637032 | lld:pubmed |
